A prospective randomized controlled trial of preimplantation genetic screening in the “good prognosis” patient

ObjectiveTo determine whether the routine use of preimplantation genetic screening (PGS) in “good prognosis” women improves in vitro fertilization (IVF) cycle outcome.DesignRandomized, controlled, prospective clinical study.SettingPrivate infertility clinic.Patient(s)Infertile women predicted to have a good prognosis as defined by: age <39 years, normal ovarian reserve, body mass index <30 kg/m2, presence of ejaculated sperm, normal uterus, ≤2 previous failed IVF cycles.Intervention(s)Patients were randomized to the PGS group or the control group on day 3 after oocyte retrieval; 23 women underwent blastomere biopsy on day 3 after fertilization (PGS group), and 24 women underwent routine IVF (control group). All embryos were transferred on day 5 or 6 after fertilization.Main Outcome Measure(s)Pregnancy, implantation, multiple gestation, and live birth rates.Result(s)No statistically significant differences were found between the PGS and control groups with respect to clinical pregnancy rate (52.4% versus 72.7%). However, the embryo implantation rate was statistically significantly lower for the PGS group (31.7% versus 62.3%) as were the live birth rate (28.6% versus 68.2%) and the multiple birth rate (9.1% versus 46.7%).Conclusion(s)In a “good prognosis” population of women, PGS does not appear to improve pregnancy, implantation, or live birth rates.